Posted in

Breakthrough! IIT-M & ICMR-NIRRCH Uncover New Fungal Infection Fight

•Posted inMedical Updates
Young doctor studying cardiology online while balancing hospital duties

Fungal infections pose a significant global health challenge, causing millions of deaths annually, particularly among immunocompromised individuals. Notably, Candida albicans (CAL) is a prevalent fungal pathogen responsible for life-threatening systemic candidiasis. New research from India introduces a groundbreaking strategy for Candida albicans treatment, aiming to combat this deadly fungus more effectively.

Addressing the Urgent Need for New Antifungal Strategies

Traditional antifungal therapies frequently encounter limitations due to rising drug resistance, toxicity, and inadequate treatment options. For this reason, novel approaches are urgently required to diversify and enhance antifungal drug development. In fact, current drug discovery methods often rely on time-consuming, inefficient trial-and-error screening.

A collaborative team of researchers from the Wadhwani School of Data Science and AI (WSAI) at IIT-Madras and the ICMR-National Institute for Research in Reproductive and Child Health (ICMR-NIRRCH) developed a novel method. Their integrated systems biology approach combines computer-based modeling with laboratory experiments. This method helps to identify critical metabolic vulnerabilities in Candida albicans that traditional lab cultures often miss.

Uncovering Metabolic Weaknesses for Candida albicans Treatment

The research team created an integrated metabolic model of the human body (Recon3D) and the CAL fungal metabolism (iRV781). This allowed them to simulate how the fungus behaves inside the human body during an infection. Consequently, they pinpointed weaknesses in fungal metabolism. Interestingly, a key finding highlighted the crucial role of arginine metabolism in the fungus’s ability to cause disease.

Moreover, the study identified an enzyme called ALT1 as a ‘metabolic bottleneck’ in CAL virulence. Importantly, when researchers deleted ALT1, the fungus showed significantly reduced infection capability in both cell-based and mouse model studies. This finding suggests a promising new target for developing effective Candida albicans treatment options.

The Significant Impact of Candida albicans Infections

Candida albicans normally resides harmlessly in various parts of the human body, including the mouth, throat, gut, vagina, and skin. However, in individuals with weakened immunity, it can spread into the bloodstream and internal organs, leading to systemic candidiasis. In severe cases, this invasive infection can kill up to 63.6% of patients.

The burden of Candida infections is particularly high in India. Annually, India reports around 4.7 lakh (470,000) cases of systemic candidiasis. Globally, approximately 1.6 million people are affected, resulting in nearly 1 million deaths each year. Estimates indicate that the annual incidence of candidemia across India is about 188,035 cases, potentially reaching 470,000 when accounting for blood culture sensitivity. Thus, the need for advanced Candida albicans treatment strategies remains critical.

Future Directions for Antifungal Therapies

The research, led by Prof. Karthik Raman of IIT-M and Prof. Susan Thomas of ICMR-NIRRCH, was published in ‘Cell Communication and Signaling’. Prof. Raman stated that the team has validated preliminary findings in animal models. The next crucial step involves collaborating with clinical partners. This will allow testing these insights on patient samples. Additionally, working with industry partners will facilitate the development of new antifungal treatments. This innovative approach holds significant potential for improving patient survival, reducing mortality, and lowering treatment costs, especially given the rise of drug-resistant strains.

Frequently Asked Questions

Q1: What is the new approach to fighting Candida albicans infections?

A: Researchers from IIT-M and ICMR-NIRRCH developed an integrated systems biology approach. This method combines computer-based modeling with laboratory experiments to identify metabolic vulnerabilities in Candida albicans that are not detectable through standard lab cultures.

Q2: How does this research help with Candida albicans treatment?

A: The study identified arginine metabolism as crucial for fungal pathogenicity and pinpointed the ALT1 enzyme as a metabolic bottleneck in the fungus’s virulence. Targeting this enzyme reduces the fungus’s ability to cause infection, offering a new pathway for developing effective treatments.

Q3: What is the impact of Candida albicans infections in India?

A: Candida albicans causes systemic candidiasis, which has a high mortality rate of up to 63.6% in severe cases. India reports approximately 4.7 lakh (470,000) cases annually, contributing to a global death toll of nearly 1 million people each year. This underscores the urgent need for better Candida albicans treatment options.

References

  1. New approach to fight fungal infection that claims one million lives annually – ETHealthworld
  2. Novel Strategies for Preventing Fungal Infections—Outline – MDPI.
  3. New Strategies to Combat Human Fungal Infections – PMC.
  4. Researchers pioneer unique systems biology approach against fungal pathogens.
  5. Novel Strategies for Preventing Fungal Infections-Outline – PubMed.
  6. New Drugs and Other Strategies for the Treatment of Fungal Infections.
  7. ICMR, IIT-M, Wadhwani develop novel way against Candida, a lethal fungal pathogen.
  8. New approach to fight fungal infection that claims one million lives annually | Chennai News.
  9. Professors from IIT-M, ICMR-NIRRCH develop biological approach against fungal pathogen.
  10. Promising new strategy to combat fungal infections – News-Medical.net.
  11. India has one of the highest rates of Candida bloodstream infection in the world – Gaffi.
  12. Burden of serious fungal infections in India – CIDRAP.
  13. ICMR researchers develop new approach to tackle fungal pathogens – Mid-day.
  14. Candida infections in ICU settings: scenario in India and Asia.
  15. EpiCandIn: An open online resource for epidemiology of Candida infections in India.

Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.